Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

MicrofluidX Demonstrate The Cyto Engine

Banner
Watch Now
Phacilitate
2 February 2023
SHARE NOW
ATW
Automation & Digitisation
Cell Therapy
Gene Therapy
Logistics
In this Tech Demo, James Kusena, Vice President of Bioprocessing and Applications at MicrofluidX, tells us about their core technology, The Cyto Engine, as seen at Advanced Therapies Week 2023. 

The Cyto Engine addresses the difficulties of translating, manufacturing and commercialising cell therapies in a cost effective manner.

James explains how this technology has demonstrated to offer superior process efficiency, repeatability and cell health.

This demo has been produced in partnership with MicrofluidX.

More like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023

Discover more like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

Broken String Bioscience Closes $15M Series A Funding Round

FDA Delays the Review of Iovance’s BLA Treatment of Advanced Melanoma

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022